Navigation Links
PeriGen, Inc. Introduces New, Advanced Perinatal System at National Perinatal Nursing Convention
Date:6/22/2012

PRINCETON, N.J., June 22, 2012 /PRNewswire/ -- PeriGen, Inc., an innovative, national provider of fetal surveillance systems, will introduce its newest and most advanced electronic fetal monitoring system, PeriCALM® Plus™, at the Association of Women's Health, Obstetric and Neonatal Nurses (AWHONN) 2012 Annual Convention, being held June 23-28, 2012 in National Harbor, Maryland.

(Logo:  http://photos.prnewswire.com/prnh/20110512/PH01144LOGO )

The PeriCALM® Plus™ suite is the only fetal surveillance system available today that provides automated visual cues that enable clinicians to easily and quickly spot clinically significant trends. This feature, known as PeriGen Visual Cueing™, provides an instant view of mothers' and babies' current status and trends over time, helping clinicians to avoid errors, increase patient safety and reduce risk. Importantly, Visual Cueing in PeriCALM Plus is supplemented by real-time, advanced decision-making support based on expert analysis and established labor and delivery protocols.

"Nurses are a driving force behind patient safety initiatives, so we could not be more pleased to be introducing PeriCALM Plus to the AWHONN conference attendees first-hand," said Matt Sappern, CEO of PeriGen. "Our goal is to support their efforts to improve perinatal outcomes for mothers and babies by creating innovative, intuitive technologies that directly impact the quality of care."

All of PeriGen's fetal monitoring systems include patented, pattern-recognition software, which offers an objective interpretation of fetal heart rate tracings that is comparable to the analyses of recognized clinical experts. PeriCALM Plus couples PeriGen's traditional fetal monitoring suite (PeriCALM) with comprehensive nursing and physician documentation, as well as protocol-driven decision support.

"PeriCALM Plus represents
'/>"/>

SOURCE PeriGen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
2. Pernix Therapeutics Introduces Omeclamox-Pak®, First Product in Gastroenterology Portfolio
3. Richard Wolf Medical Instruments introduces groundbreaking 5514 Endocam Performance HD
4. Rochester Medical Introduces Magic3® Coude Tip Hydrophilic Intermittent Catheter
5. Velos, Inc. Introduces Mobile App for Oncology Adverse Events and Graft-Versus-Host Disease at 2012 ASCO Annual Meeting
6. IDEV Technologies Introduces SurePath™ Guidewires
7. ConvaTec Introduces Enhanced Flexi-Seal® SIGNAL® FMS
8. HealthONE® Introduces the Colorado Center for Robotic Surgery(SM)
9. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
10. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
11. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
(Date:12/24/2014)...  Commonwealth Cornerstone Group (CCG) today announced the completion of ... to help fund the expansion and consolidation of healthcare services ... . PHN is the largest federally ... It is the largest employer in Sharon,s ... staff. Currently, PHN Sharon offers scattered services out ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals announced ... KX2-361 at Roswell Park Cancer Institute. KX2-361 ... drug that has shown potent inhibitory activity against a ... that are resistant to Temozolomide (T98G), the most widely ... a well-established brain tumor mouse model, KX2-361 consistently clears ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO ) today ... Total revenue was $2.6 million and $8.2 million for the ... million and $3.8 million for the same periods in 2010. ... September 30, 2011, were $9.0 million and $24.0 million as compared ...
... UCB today announced new ... (certolizumab pegol) was associated with a rapid and sustained ... of moderate to severe rheumatoid arthritis (RA) patients. The ... 2011 Annual Scientific Meeting in Chicago, November 5-9, are ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 2New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 3New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 4New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 5New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 6New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 7New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 8New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 10New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 11
(Date:12/26/2014)... December 26, 2014 Yisrayl Hawkins, Pastor at ... open letter in light of the Ferguson, Missouri unrest. Yisrayl ... civil unrest and explains why it has only increased. ... was even created. He says there is a very specific ... also says there is a set of rules, or Laws ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 Pentec Health, ... in the state of Pennsylvania for 2014. The awards ... statewide programs of its kind in the country. The ... the Pennsylvania Department of Community and Economic Development, the ... Management and the Central Penn Business Journal. ...
(Date:12/25/2014)... The click strand woven bamboo flooring ... Today, the business announces a click strand woven ... 30, 2015. , Click strand woven bamboo flooring ... a well-known brand in the bamboo industry. It ... reliable bamboo flooring supplier. , “We are happy ...
(Date:12/25/2014)... the popular online supplier of wedding dresses and special occasion ... black one-shoulder cocktail dresses . In addition, all these elegant ... prices, up to 70% off. , The development ... You know, we have thousands of frequent callers in the ... can visit our website for more details. The current special ...
(Date:12/25/2014)... California (PRWEB) December 25, 2014 Helen ... home in Woodland Hills, California after an 8 year ... away on Christmas Eve evening in her home in ... aggressive metastatic breast cancer. , As ... over forty years, she pioneered and championed many of ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... Improving Healthcare , , PLANO, Texas, Dec. 5 Edition 1 ... Vice President and Chief Medical, ... Vice President for Marwood Group, What: "Looking Forward: Perspectives ... hosted by Dr. Harry Greenspun, Executive Vice President and, ...
... another reason to quit smoking, consider that it may diminish ... the University of Rochester Medical Center have found that women ... were significantly more likely to face fertility problems and suffer ... non-smoking women showed those who were exposed to second hand ...
... The board of directors,for Hillenbrand, Inc. (NYSE: ... of $0.185 per share on the company,s common stock, ... $0.1825 per share. The dividend,is payable Dec. 31, 2008, ... Dec. 17, 2008. Hillenbrand has paid quarterly dividends since ...
... at 62nd Annual Meeting of the American Epilepsy Society , ... New studies presented at the 62nd annual meeting of the ... the course of epilepsy diagnosis and management to improve the ... These studies are among the hundreds of developments in the ...
... State Budget Crisis Threaten Seniors, Access to Quality Care, LTC ... Dec. 5 Commenting on the legislative year ahead ... comments today that skilled nursing facilities (SNFs) should not receive ... the nation,s leading long term care advocacy organizations today said ...
... skills , , FRIDAY, Dec. 5 (HealthDay News) -- College students ... might want to get some sleep instead. And not just ... test. , That,s the message from a new study that ... you learn during the day. , Study participants who learned ...
Cached Medicine News:Health News:Looking Forward: Perspectives on Healthcare and Information Technology 2Health News:Looking Forward: Perspectives on Healthcare and Information Technology 3Health News:Secondhand smoke raises odds of fertility problems in women 2Health News:New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management 2Health News:New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management 3Health News:New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management 4Health News:New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management 5Health News:Long Term Care Sector Supports and Is Well-Positioned to Advance Health Care Reform, Bolster Economic Stimulus 2Health News:Long Term Care Sector Supports and Is Well-Positioned to Advance Health Care Reform, Bolster Economic Stimulus 3Health News:To Sleep, Perchance to Remember 2Health News:To Sleep, Perchance to Remember 3
Platelet Aggregation Profiler...
... Eclipse,Plus or 850 ECG medical ... capability. Doctors,maintain all the benefits ... and gain the,ability to view ... personal computers., With diagnostic-quality viewing ...
... The Vision5L Digital ... 5- or 7-lead, ... a signal preview,screen. ... using a compact,flash ...
... provides three contrast levels (high, 9.5 % and ... This test is designed to detect very subtle ... lens evaluation or due to refractive surgery. The ... same contrast and acuity levels as the lower ...
Medicine Products: